Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The innate immune system plays a major role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Recently we reported complement activation in human NASH. However, it remained unclear whether the alternative pathway of complement, which amplifies C3 activation and which is frequently associated with pathological complement activation leading to disease, was involved. Here, alternative pathway components were investigated in liver biopsies of obese subjects with healthy livers (n = 10) or with NASH (n = 12) using quantitative PCR, Western blotting, and immunofluorescence staining. Properdin accumulated in areas where neutrophils surrounded steatotic hepatocytes, and colocalized with the C3 activation product C3c. C3 activation status as expressed by the C3c/native C3 ratio was 2.6-fold higher (p<0.01) in subjects with NASH despite reduced native C3 concentrations (0.94±0.12 vs. 0.57±0.09; p<0.01). Hepatic properdin levels positively correlated with levels of C3c (rs = 0.69; p<0.05) and C3c/C3 activation ratio (rs = 0.59; p<0.05). C3c, C3 activation status (C3c/C3 ratio) and properdin levels increased with higher lobular inflammation scores as determined according to the Kleiner classification (C3c: p<0.01, C3c/C3 ratio: p<0.05, properdin: p<0.05). Hepatic mRNA expression of factor B and factor D did not differ between subjects with healthy livers and subjects with NASH (factor B: 1.00±0.19 vs. 0.71±0.07, p = 0.26; factor D: 1.00±0.21 vs. 0.66±0.14, p = 0.29;). Hepatic mRNA and protein levels of Decay Accelerating Factor tended to be increased in subjects with NASH (mRNA: 1.00±0.14 vs. 2.37±0.72; p = 0.22; protein: 0.51±0.11 vs. 1.97±0.67; p = 0.28). In contrast, factor H mRNA was downregulated in patients with NASH (1.00±0.09 vs. 0.71±0.06; p<0.05) and a similar trend was observed with hepatic protein levels (1.12±0.16 vs. 0.78±0.07; p = 0.08). Collectively, these data suggest a role for alternative pathway activation in driving hepatic inflammation in NASH. Therefore, alternative pathway factors may be considered attractive targets for treating NASH by inhibiting complement activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“C3 complement protein is increased in human metabolic dysfunction–associated steatohepatitis (MASH) livers, and the activation of the alternative complement pathway is associated with disease hallmarks [38].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 4×
“In contrast, we observed a gradual increase in C3c levels with a higher lobular inflammation score as determined by the Kleiner classification ((1) 0.7360.11 vs. (2) 1.5160.27 vs. (3) 4.4361.00; p,0.01; figure 4C).”
InfluentialNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654 · cited 1×
“Neutrophils, an important component of inflammation in NASH [11,12], are guided toward sites of complement activation by C3a and C5a, and stimulated to perform phagocytosis [34].”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 856
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature · doi:10.1038/nature10449 · Cited by 533 · cited 1×
“Low factor H expression may also play a role in the detrimental effects of lipid peroxidation products in NASH [12,23], since factor H was recently shown to recognize epitopes associated with oxidative stress and to mediate their neutralization [24].”
BackgroundComplement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Tosello-Trampont, A.-C., Landes, S. G., Nguyen, V., Novobrantseva, T. I., & Hahn, Y. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417014 · Cited by 415
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis
Rensen, S. S., Slaats, Y., Nijhuis, J., Jans, A., Bieghs, V., Driessen, A., Malle, E., Greve, J. W., & Buurman, W. A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080999 · Cited by 290
Self-citation
Cited by
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
The Role of Complement in Liver Injury, Regeneration, and Transplantation
Thorgersen, E. B., Barratt‐Due, A., Haugaa, H., Harboe, M., Pischke, S. E., Nilsson, P. H., & Mollnes, T. E. (2019) · Hepatology · doi:10.1002/hep.30508 · Cited by 240
“(28) Thus, NASH and related HCC could be decreased by inhibition of a constantly activated complement system, for instance, by targeting the alternative pathway.(29)”
Background(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Properdin: A multifaceted molecule involved in inflammation and diseases
Chen, J. Y., Cortés, C., & Ferreira, V. P. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.018 · Cited by 99
The virtuous cycle of human genetics and mouse models in drug discovery
Nadeau, J. H., & Auwerx, J. H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0009-9 · Cited by 83
Metadata
- Authors
- Segers, F. M., Verdam, F. J., de Jonge, C., Boonen, B., Driessen, A., Shiri-Sverdlov, R., Bouvy, N. D., Greve, J. W. M., Buurman, W. A., & Rensen, S. S.
- Affiliations
- Maastricht University Medical Centre (NL)
- Atrium Medisch Centrum Parkstad (NL)
- Corresponding author
- Rensen, Sander S.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-09
- Volume
- 9
- Issue
- 10
- Pages
- e110053
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4192551
- OpenAlex
- W2008456888
- Cited by
- 50
- References
- 40
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 1
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, cc-by)
- Funders
- Rijksdienst voor Ondernemend Nederland
- Transnationale Universiteit Limburg
- SenterNovem
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, alternative complement pathway, properdin, C3 activation, C3c, CD55, complement factor H, factor B, factor D, liver inflammation, innate immunity, hepatic steatosis, obesity, neutrophils
- MeSH terms
- Adult, Biopsy, Complement Pathway, Alternative, Complement C3, Gene Expression Regulation, Humans, Inflammation, Liver, Properdin, Complement Factor B, Complement Factor D, RNA, Messenger, Complement Factor H, Complement C3-C5 Convertases, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.1371/journal.pone.0110053
- The paper
- Segers, F. M., Verdam, F. J., de Jonge, C., Boonen, B., Driessen, A., Shiri-Sverdlov, R., Bouvy, N. D., Greve, J. W. M., Buurman, W. A., & Rensen, S. S. (2014). Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis. PLoS ONE. https://doi.org/10.1371/journal.pone.0110053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.